Presented at #ESMO26: Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu @myESMO
A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

Oct 25, 2026 · 9:20 AM UTC

3
101
10
343
32,400